Director, Commercial Analytics & Information
Posted 3 Sep 2026
Advertised as “Director, Commercial Analytics & Information ”
BranchFactor Summary
The original posting with the fluff stripped out
- Expected experience
- 10+ yrs
- Management level
- People management
No salary listed for this role.
Field of studyBusiness, Life Sciences, Quantitative
Study levelBachelor's
Study levelGraduate certificate or higher
About Summit:
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.
Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:
Non-small Cell Lung Cancer (NSCLC)
-
HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
-
HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
-
HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.
Colorectal Cancer (CRC)
- HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Location: Princeton, NJ
Overview of Role:
The Director, Commercial Analytics & Information turns Summit's commercial data into decisions. This role owns launch analytics, performance reporting, dashboards, and the field-facing insight products that tell Sales and Marketing what is working and what is not. The role sets the definitions behind every commercial metric and is the final word on what a number means, so that Sales, Marketing, Finance, and Commercial Operations are all working from the same figure. This leader consumes the data assets owned by Commercial Data Management & Strategy and partners with Business Information on the tools that deliver analysis. Because ivonescimab is an intravenous buy-and-bill product, this role must be able to build a credible performance picture from purchase and claims data rather than from prescription data, and must be explicit about what that picture can and cannot show.